The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes.
Yvonne Adu-AgyeiwaahMaria B GrantAlexander G ObukhovPublished in: Cells (2020)
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the ongoing coronavirus disease 2019 (COVID-19) pandemic, with more than 50 million cases reported globally. Findings have consistently identified an increased severity of SARS-CoV-2 infection in individuals with diabetes. Osteopontin, a cytokine-like matrix-associated phosphoglycoprotein, is elevated in diabetes and drives the expression of furin, a proprotein convertase implicated in the proteolytic processing and activation of several precursors, including chemokines, growth factors, hormones, adhesion molecules, and receptors. Elevated serum furin is a signature of diabetes mellitus progression and is associated with a dysmetabolic phenotype and increased risk of diabetes-linked premature mortality. Additionally, furin plays an important role in enhancing the infectivity of SARS-CoV-2 by promoting its entry and replication in the host cell. Here, we hypothesize that diabetes-induced osteopontin and furin protein upregulation results in worse outcomes in diabetic patients with SARS-CoV-2 infection owing to the roles of these protein in promoting viral infection and increasing metabolic dysfunction. Thus, targeting the osteopontin-furin axis may be a plausible strategy for reducing mortality in SARS-CoV-2 patients with diabetes.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- coronavirus disease
- type diabetes
- glycemic control
- cardiovascular disease
- poor prognosis
- cardiovascular events
- long non coding rna
- cell proliferation
- mesenchymal stem cells
- weight loss
- single cell
- coronary artery disease
- stem cells
- cystic fibrosis
- binding protein
- adipose tissue
- endothelial cells
- escherichia coli
- oxidative stress
- insulin resistance
- pseudomonas aeruginosa
- drug delivery
- cell therapy